Cerus Corporation (CERS): Price and Financial Metrics


Cerus Corporation (CERS): $4.84

0.01 (+0.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CERS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CERS POWR Grades


  • Sentiment is the dimension where CERS ranks best; there it ranks ahead of 85.85% of US stocks.
  • CERS's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • CERS ranks lowest in Momentum; there it ranks in the 16th percentile.

CERS Stock Summary

  • CERS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 152.65 -- higher than 83.92% of US-listed equities with positive expected earnings growth.
  • CERS's price/sales ratio is 6.24; that's higher than the P/S ratio of 77.01% of US stocks.
  • With a year-over-year growth in debt of 30.94%, Cerus Corp's debt growth rate surpasses 78.24% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Cerus Corp, a group of peers worth examining would be GBT, BLI, SMTC, PDEX, and QUIK.
  • Visit CERS's SEC page to see the company's official filings. To visit the company's web site, go to www.cerus.com.

CERS Valuation Summary

  • In comparison to the median Healthcare stock, CERS's price/sales ratio is 123.68% higher, now standing at 8.5.
  • Over the past 243 months, CERS's price/earnings ratio has gone up 0.4.
  • Over the past 243 months, CERS's EV/EBIT ratio has gone down 4.9.

Below are key valuation metrics over time for CERS.

Stock Date P/S P/B P/E EV/EBIT
CERS 2021-08-31 8.5 13.1 -18.0 -19.8
CERS 2021-08-30 8.4 13.0 -17.8 -19.6
CERS 2021-08-27 8.4 12.9 -17.7 -19.5
CERS 2021-08-26 8.0 12.4 -17.1 -18.8
CERS 2021-08-25 8.2 12.6 -17.3 -19.1
CERS 2021-08-24 8.2 12.7 -17.5 -19.2

CERS Growth Metrics

    Its 3 year price growth rate is now at 19.24%.
  • Its 3 year revenue growth rate is now at 137.09%.
  • The 5 year net cashflow from operations growth rate now stands at -31.06%.
CERS's revenue has moved up $125,355,000 over the prior 70 months.

The table below shows CERS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 159.518 -33.922 -54.374
2021-09-30 143.02 -41.158 -59.636
2021-06-30 130.11 -39.255 -61.338
2021-03-31 119.174 -38.917 -60.848
2020-12-31 114.249 -40.743 -59.857
2020-09-30 107.147 -40.846 -62.399

CERS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CERS has a Quality Grade of C, ranking ahead of 39.02% of graded US stocks.
  • CERS's asset turnover comes in at 0.647 -- ranking 61st of 186 Medical Equipment stocks.
  • BSGM, NVCR, and STRR are the stocks whose asset turnover ratios are most correlated with CERS.

The table below shows CERS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.647 0.607 -0.310
2021-06-30 0.592 0.619 -0.303
2021-03-31 0.547 0.631 -0.294
2020-12-31 0.528 0.640 -0.286
2020-09-30 0.529 0.643 -0.318
2020-06-30 0.530 0.654 -0.360

CERS Price Target

For more insight on analysts targets of CERS, see our CERS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 1.2 (Strong Buy)

CERS Stock Price Chart Interactive Chart >

Price chart for CERS

CERS Price/Volume Stats

Current price $4.84 52-week high $8.06
Prev. close $4.83 52-week low $4.38
Day low $4.72 Volume 1,790,500
Day high $4.97 Avg. volume 1,894,693
50-day MA $5.09 Dividend yield N/A
200-day MA $5.94 Market Cap 856.19M

Cerus Corporation (CERS) Company Bio


Cerus Corporation operates as a biomedical products company which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company was founded in 1991 and is based in Concord, California.


CERS Latest News Stream


Event/Time News Detail
Loading, please wait...

CERS Latest Social Stream


Loading social stream, please wait...

View Full CERS Social Stream

Latest CERS News From Around the Web

Below are the latest news stories about Cerus Corp that investors may wish to consider to help them evaluate CERS as an investment opportunity.

Cerus Corporation to Participate at the Cowen 42nd Annual Health Care Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST. A live webcast of the event will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event. ABOUT CERUS Cerus Co

Business Wire | February 25, 2022

Cerus Reports Narrower Quarterly Loss As INTERCEPT Platelet Kits Lift Q4 Sales

Cerus Corp''s (NASDAQ: CERS ) Q4 FY21 product revenue was $39.9 million , compared to $28.2 million, driven by increased sales of INTERCEPT platelet kits to blood center customers across the U.S. Total revenue increased 49% to $50.1 million, beating the consensus of $44.2 million. Product gross profit was $20.4 million and, for the second consecutive quarter, was the highest in the company''s history, Full story available on Benzinga.com

Benzinga | February 23, 2022

Does Cerus (CERS) Have the Potential to Rally 90% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | February 23, 2022

Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021. Recent developments and highlights include: Fourth quarter 2021 total revenue of $50.1 million, reflecting a 49% increase over the prior year period. For the full year, 2021 total revenue was $159.5 million, reflecting a 40% increase over the prior year period. Total revenue was composed of (in thousands, except %): Three Months E

Business Wire | February 22, 2022

Cerus Corporation (CERS) CEO Obi Greenman on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 22, 2022

Read More 'CERS' Stories Here

CERS Price Returns

1-mo 5.91%
3-mo -16.41%
6-mo -30.66%
1-year -17.41%
3-year -6.74%
5-year 105.96%
YTD -28.93%
2021 -1.59%
2020 63.98%
2019 -16.77%
2018 50.00%
2017 -22.30%

Continue Researching CERS

Want to see what other sources are saying about Cerus Corp's financials and stock price? Try the links below:

Cerus Corp (CERS) Stock Price | Nasdaq
Cerus Corp (CERS) Stock Quote, History and News - Yahoo Finance
Cerus Corp (CERS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7463 seconds.